FDA has granted Breakthrough Therapy designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor exon 20 insertion mutations who have previously received platinum-based systemic chemotherapy.
FDA has granted Fast Track designation to Reqorsa (quaratusugene ozeplasmid), a pan-kinase inhibitor, plus Keytruda (pembrolizumab) in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.
Rain Therapeutics Inc. and Roche have entered a clinical supply agreement for the anti-PD-L1 monoclonal antibody Tecentriq (atezolizumab).
The National Cancer Institute approved the following clinical research studies last month.
NCI is temporarily reducing its paylines as the federal government is being funded at FY2021 levels via another continuing resolution, delaying the budgeting process for most federal agencies in the new fiscal year.
Congress has extended FY22 spending talks once again, leaving the proposed Advanced Research Projects Agency for Health (ARPA-H)—a key piece of President Joe Biden’s cancer agenda—in limbo.
God did not intend directors of NCI-designated cancer centers to last in their jobs forever.
A $25 million gift from life sciences entrepreneur and investor Pablo Legorreta and his wife, Almudena, will support the development of Brown University’s recently launched cancer center.
City of Hope has entered a definitive agreement to acquire Cancer Treatment Centers of America, a network of oncology hospitals and outpatient care centers across the United States (The Cancer Letter, May 7, 2021).
Case Western Reserve University and its academic medical center partners, Cleveland Clinic and University Hospitals, which together form the consortium of the NCI designated comprehensive cancer center, are recruiting the next director for the Case Comprehensive Cancer Center.
